The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Capecitabine-Global Market Insights and Sales Trends 2025
Synopsis
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
The global Capecitabine market size is expected to reach US$ 997.5 million by 2029, growing at a CAGR of -0.4% from 2023 to 2029. The market is mainly driven by the significant applications of Capecitabine in various end use industries. The expanding demands from the Breast Cancer, Colorectal Cancer and Stomach Cancer,, are propelling Capecitabine market. 500 mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 150 mg segment is estimated at % CAGR for the next seven-year period.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Capecitabine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Capecitabine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Capecitabine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Capecitabine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Capecitabine covered in this report include Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group and Hetero, etc.
The global Capecitabine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Global Capecitabine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Capecitabine market, Segment by Type:
500 mg
150 mg
Global Capecitabine market, by Application
Breast Cancer
Colorectal Cancer
Stomach Cancer
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Capecitabine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Capecitabine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
The global Capecitabine market size is expected to reach US$ 997.5 million by 2029, growing at a CAGR of -0.4% from 2023 to 2029. The market is mainly driven by the significant applications of Capecitabine in various end use industries. The expanding demands from the Breast Cancer, Colorectal Cancer and Stomach Cancer,, are propelling Capecitabine market. 500 mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 150 mg segment is estimated at % CAGR for the next seven-year period.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Capecitabine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Capecitabine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Capecitabine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Capecitabine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Capecitabine covered in this report include Roche, Teva, Mylan, Hikma, Hengrui Medicine, Cipla, Reliance Group and Hetero, etc.
The global Capecitabine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Global Capecitabine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Capecitabine market, Segment by Type:
500 mg
150 mg
Global Capecitabine market, by Application
Breast Cancer
Colorectal Cancer
Stomach Cancer
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Capecitabine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Capecitabine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Capecitabine Market Overview
1.1 Capecitabine Product Overview
1.2 Capecitabine Market Segment by Type
1.2.1 500 mg
1.2.2 150 mg
1.3 Global Capecitabine Market Size by Type
1.3.1 Global Capecitabine Market Size Overview by Type (2018-2029)
1.3.2 Global Capecitabine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Capecitabine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Capecitabine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Capecitabine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Capecitabine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Capecitabine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Capecitabine Sales Breakdown by Type (2018-2023)
2 Global Capecitabine Market Competition by Company
2.1 Global Top Players by Capecitabine Sales (2018-2023)
2.2 Global Top Players by Capecitabine Revenue (2018-2023)
2.3 Global Top Players by Capecitabine Price (2018-2023)
2.4 Global Top Manufacturers Capecitabine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Capecitabine Market Competitive Situation and Trends
2.5.1 Capecitabine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Capecitabine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Capecitabine as of 2022)
2.7 Date of Key Manufacturers Enter into Capecitabine Market
2.8 Key Manufacturers Capecitabine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Capecitabine Status and Outlook by Region
3.1 Global Capecitabine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Capecitabine Historic Market Size by Region
3.2.1 Global Capecitabine Sales in Volume by Region (2018-2023)
3.2.2 Global Capecitabine Sales in Value by Region (2018-2023)
3.2.3 Global Capecitabine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Capecitabine Forecasted Market Size by Region
3.3.1 Global Capecitabine Sales in Volume by Region (2024-2029)
3.3.2 Global Capecitabine Sales in Value by Region (2024-2029)
3.3.3 Global Capecitabine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Capecitabine by Application
4.1 Capecitabine Market Segment by Application
4.1.1 Breast Cancer
4.1.2 Colorectal Cancer
4.1.3 Stomach Cancer
4.2 Global Capecitabine Market Size by Application
4.2.1 Global Capecitabine Market Size Overview by Application (2018-2029)
4.2.2 Global Capecitabine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Capecitabine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Capecitabine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Capecitabine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Capecitabine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Capecitabine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Capecitabine Sales Breakdown by Application (2018-2023)
5 North America Capecitabine by Country
5.1 North America Capecitabine Historic Market Size by Country
5.1.1 North America Capecitabine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Capecitabine Sales in Volume by Country (2018-2023)
5.1.3 North America Capecitabine Sales in Value by Country (2018-2023)
5.2 North America Capecitabine Forecasted Market Size by Country
5.2.1 North America Capecitabine Sales in Volume by Country (2024-2029)
5.2.2 North America Capecitabine Sales in Value by Country (2024-2029)
6 Europe Capecitabine by Country
6.1 Europe Capecitabine Historic Market Size by Country
6.1.1 Europe Capecitabine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Capecitabine Sales in Volume by Country (2018-2023)
6.1.3 Europe Capecitabine Sales in Value by Country (2018-2023)
6.2 Europe Capecitabine Forecasted Market Size by Country
6.2.1 Europe Capecitabine Sales in Volume by Country (2024-2029)
6.2.2 Europe Capecitabine Sales in Value by Country (2024-2029)
7 Asia-Pacific Capecitabine by Region
7.1 Asia-Pacific Capecitabine Historic Market Size by Region
7.1.1 Asia-Pacific Capecitabine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Capecitabine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Capecitabine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Capecitabine Forecasted Market Size by Region
7.2.1 Asia-Pacific Capecitabine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Capecitabine Sales in Value by Region (2024-2029)
8 Latin America Capecitabine by Country
8.1 Latin America Capecitabine Historic Market Size by Country
8.1.1 Latin America Capecitabine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Capecitabine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Capecitabine Sales in Value by Country (2018-2023)
8.2 Latin America Capecitabine Forecasted Market Size by Country
8.2.1 Latin America Capecitabine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Capecitabine Sales in Value by Country (2024-2029)
9 Middle East and Africa Capecitabine by Country
9.1 Middle East and Africa Capecitabine Historic Market Size by Country
9.1.1 Middle East and Africa Capecitabine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Capecitabine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Capecitabine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Capecitabine Forecasted Market Size by Country
9.2.1 Middle East and Africa Capecitabine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Capecitabine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Roche
10.1.1 Roche Company Information
10.1.2 Roche Introduction and Business Overview
10.1.3 Roche Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Roche Capecitabine Products Offered
10.1.5 Roche Recent Development
10.2 Teva
10.2.1 Teva Company Information
10.2.2 Teva Introduction and Business Overview
10.2.3 Teva Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Teva Capecitabine Products Offered
10.2.5 Teva Recent Development
10.3 Mylan
10.3.1 Mylan Company Information
10.3.2 Mylan Introduction and Business Overview
10.3.3 Mylan Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Mylan Capecitabine Products Offered
10.3.5 Mylan Recent Development
10.4 Hikma
10.4.1 Hikma Company Information
10.4.2 Hikma Introduction and Business Overview
10.4.3 Hikma Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Hikma Capecitabine Products Offered
10.4.5 Hikma Recent Development
10.5 Hengrui Medicine
10.5.1 Hengrui Medicine Company Information
10.5.2 Hengrui Medicine Introduction and Business Overview
10.5.3 Hengrui Medicine Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Hengrui Medicine Capecitabine Products Offered
10.5.5 Hengrui Medicine Recent Development
10.6 Cipla
10.6.1 Cipla Company Information
10.6.2 Cipla Introduction and Business Overview
10.6.3 Cipla Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Cipla Capecitabine Products Offered
10.6.5 Cipla Recent Development
10.7 Reliance Group
10.7.1 Reliance Group Company Information
10.7.2 Reliance Group Introduction and Business Overview
10.7.3 Reliance Group Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Reliance Group Capecitabine Products Offered
10.7.5 Reliance Group Recent Development
10.8 Hetero
10.8.1 Hetero Company Information
10.8.2 Hetero Introduction and Business Overview
10.8.3 Hetero Capecitabine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Hetero Capecitabine Products Offered
10.8.5 Hetero Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Capecitabine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Capecitabine Industrial Chain Analysis
11.4 Capecitabine Market Dynamics
11.4.1 Capecitabine Industry Trends
11.4.2 Capecitabine Market Drivers
11.4.3 Capecitabine Market Challenges
11.4.4 Capecitabine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Capecitabine Distributors
12.3 Capecitabine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
